摘要
目的观察利拉鲁肽（Liraglutide）对2型糖尿病（T2DM）患者血浆成纤维细胞生长因子-21（FGF-21）水平的影响。方法采用酶联免疫法测定T2DM患者及正常人血浆FGF-21水平，分析血浆FGF-21水平与BMI、WHR、稳态模型胰岛素抵抗指数（HOMA—IR）、稳态模型胰岛B细胞分泌指数（HO—MA—IS）、游离脂肪酸（FFA）等的关系，Liraglutide治疗前后T2DM患者血浆FGF-21水平的变化。结果T2DM患者血浆FGF-21水平明显高于正常对照（1．81±0．32VS1．32±0．09，P〈0．01）。T2DM患者经Liraglutide治疗后WHR、BMI、FBG、2hPBG、HbAlc和FFA均显著降低（P〈0．05或P〈0．01），而HO—MA—IS则显著增高（P〈0．01），但FGF-21变化无明显差异（P〉0．05）。
Objective To investigate the effects of Liraglutide on plasma FGF-21 level in patients with type 2 diabetes mellitus （T2DM）. Methods Enzyme linked immunosorbent assay （ELISA） was used to measure plasma FGF-21 level in patients with T2DM and normal controls （NGT）. Relationship between plasma FGF-21 level and BMI, WHR, HOMA-IR, HOMA-IS, FFA was analyzed. After Liraglutide treatment, plasma FGF-21 level was observed in patients with T2DM. Results Fasting plasma FGF-21 level was higher in T2DM patients than that in normal control group （1.81 ± 0.32 vs. 1.32 ±0.09 μg/L, P 〈 0.01 ）. After Liraglutide treatment, WHR, BMI, FPG, 2hPBG, HbAlc and FFA in T2DM patients significantly decreased （P 〈0.05 or P 〈0.01 ） , HOMA-IS remarkably increased （P 〈0.01 ） , and FGF-21 had no change. Conclusion Liraglutide and FGF-21 may have different roles in insulin resistance.
出处
《中华内分泌外科杂志》
CAS
2011年第1期49-51,共3页
Chinese Journal of Endocrine Surgery
基金
国家自然科学基金项目（30771037）
